BioMarin – a gold sponsor of the Joint Congress of ESPE and ESE 2025.
BioMarin is a global biotechnology company that relentlessly pursues bold science to translate genetic discoveries into new medicines that advance the future of human health.
Find us on booth E30 in the exhibition hall E.
All further details below will be available on the Congress webpage too.
Congress activities
Sunday 11 May 2025, 13:00 – 14:05, Hall D5
A new era in achondroplasia care: from guidelines to practice, including transition to adulthood. – A BioMarin sponsored satellite symposium.
Chair: Geert Mortier
Introduction to achondroplasia and adult care
Geert Mortier, Belgium
Key practical steps and considerations for initiating treatment with VOXZOGO®▼ (vosoritide)
Julie Hoover-Fong, USA
Guideline recommendations for monitoring during and after treatment
Melita Irving, UK
From guidelines to practice: insights from my clinical experience
Tilman Rohrer, Germany
Panel discussion – Care across the treatment pathway, including transition to adult care
All faculty
Q&A and closing remarks
Geert Mortier, Belgium
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Healthcare professionals should report adverse events in accordance with their local requirements.
Adverse events should also be reported to BioMarin on + 1 415 506 6179 or [email protected]
VOXZOGO is indicated in the EU for the treatment of achondroplasia in patients 4 months of age and older whose epiphyses are not closed.
This symposium is for Healthcare Professionals only and is organised and sponsored by BioMarin.
